Subcellular fractionation reveals differential distribution of BAP31 and cellubrevin. (a) BAP31 does not coenrich with cellubrevin (ceb) during purification of clathrin-coated vesicles from rat liver. Homogenates (H) were centrifuged for 20 min at 20,000 gmax. The supernatant (S1) was centrifuged again at 55,000 gmax for 1 h and then the pellet (P2) was resuspended and recentrifuged after adding ficoll and sucrose. The supernatant (S3) was diluted and centrifuged at 100,000 gmax for 1 h. This pellet, P4, was again resuspended and centrifuged at 20,000 gmax for 20 min. The resulting supernatant S5 was layered on top of a D2O–sucrose density gradient. The pellet obtained after centrifugation at 110,000 gmax for 2 h contained purified coated vesicles (Maycox et al., 1992). Of each fraction, 10 μg of protein were analyzed by SDS-PAGE and immunoblotting for cellubrevin and BAP31. (b) BAP31 does not coenrich with cellubrevin during purification of early endosomes (EE). Analysis of endosomal fractions. A PNS of BHK-21 cells was subjected to flotation gradient centrifugation on a discontinuous D2O–sucrose gradients (Gorvel et al., 1991), resulting in a fraction enriched in EE and a fraction enriched in late endosomes and carrier vesicles (LE). The gradient fractions were diluted and pelleted by centrifugation. Of each fraction, 10 μg of protein were analyzed by SDS-PAGE and immunoblotting for cellubrevin and BAP31, and for the EE markers TfR and Rab5. (c) BAP31 coenriches with markers of the intermediate compartment and the ER. Fractionation of ER and intermediate compartment. A PNS was mixed with Percoll to give a final density of 1.129 g/ml, and then centrifuged. A midportion of the gradient was pooled (Percoll), adjusted to 30% Nycodenz, and overlayed with 27 and 18.5% (wt/wt) of Nycodenz. After equilibrium density gradient centrifugation, three interfaces were collected (F1, F2, F3) and analyzed by SDS-PAGE and immunoblotting (10 μg of protein per lane). ER markers (PDI and calnexin) are highly enriched in the F3 fraction, together with markers for the IC (ERGIC-53 and p58). BAP31 immunoreactivity was recovered mainly in this interface, in contrast to cellubrevin, SCAMP, and the transferrin receptor, which were enriched in the F2 interface.